Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.40 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630163 | 0.86 | PTPN1 (0.43) | PTPN1CHRNA7MAOAMAOBSNRNP200 | |
| SCHEMBL4646378 | 0.81 | PTPN1 (0.51) | PTPN1CHRNA7SNRNP200BRD4 | |
| SCHEMBL646919 | 0.81 | PTPN1 (0.47) | PTPN1CHRNA7SNRNP200 | |
| SCHEMBL12056127 | 0.81 | PTPN1 (0.50) | PTPN1CHRNA7MAOB | |
| SCHEMBL3917425 | 0.81 | PTPN1 (0.47) | PTPN1SNRNP200 | |
| SCHEMBL4646906 | 0.81 | PTPN1 (0.53) | PTPN1MAOAMAOBSNRNP200 | |
| SCHEMBL4643306 | 0.81 | PTPN1 (0.53) | PTPN1 | |
| SCHEMBL3917446 | 0.81 | PTPN1 (0.47) | PTPN1CHRNA7SNRNP200 | |
| SCHEMBL3920457 | 0.81 | PTPN1 (0.61) | PTPN1SNRNP200BRD4 | |
| SCHEMBL630265 | 0.80 | PTPN1 (0.45) | PTPN1CHRNA7MAOAMAOBSNRNP200 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963292-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-7700633-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20080262050-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| EP-1963292-A2 | ORGANIC COMPOUNDS | Novartis Pharma AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067615-A2 | THIADIAZOLE DERIVATIVES AS ANTIDIABETIC AGENTS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262050-A1 | Organic Compounds | PTPRS, PTPRO, PTPRC | PTPN1 23/4885CHRNA7 4601/4885MAOA 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.